ArticleIntensive care medicine experimental2025
Unravelling the complex inflammatory landscape of COVID-19 infection: a pathway to biomarkers identification in infection-associated delirium in the ICU.
Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CCL2 and CXCL2 are markers of delirium vulnerability in community dwelling older people.Age and ageing · 2026Article
- COVID-19 infections and cognitive impairment: mechanisms and perspectives.Breathe (Sheffield, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelirium is a serious complication in patients with COVID-19-related acute respiratory distress syndrome (ARDS) admitted to the intensive care unit (ICU). Although numerous clinical risk factors have been identified, the immunologic pathways underlying delirium remain unclear. In this retrospective cohort study, we investigated high-dimensional immune signatures in ICU patients to delineate peripheral immune markers associated with delirium. We also explored machine learning (ML) approaches to enhance biomarker discovery and strengthen predictive modelling through synthetic data generation.
methodsWe studied a cohort of 62 COVID-19 ARDS patients admitted to the ICU at Lausanne University Hospital, Switzerland. The primary analysis compared patients within this cohort who developed delirium (n = 39) to those who remained delirium-free (n = 23). As a baseline for disease severity, we also compared the ICU cohort to 55 non-ICU COVID-19 patients and 450 healthy individuals. We performed high-dimensional immunophenotyping of cytokines, chemokines, and growth factors using multiplex beads assay, along with immune cell profiling via mass cytometry (CyTOF). Ridge regression has been employed to build classification models. We also generated synthetic samples using beta-variational autoencoders to improve sample size and subsequently model stability.
resultsDelirious patients exhibited a distinctive immune signature, including elevated CXCL1, CCL11, CXCL13, HGF, and VEGF-A, coupled with reduced IL-1α, IL-21, and IL-22. Alterations in immune cell populations featured increased exhausted B cells and decreases in CXCR3 + CD4 + T cells, IgM + unswitched memory B cells, and HLA-DR + activated T cells. Leveraging these high-dimensional data, we trained ridge regression models to predict delirium. Incorporating synthetic data helped stabilize the models with a best-performing model achieving an area under the curve (AUC) of 0.95, with high sensitivity (93%) and specificity (86%), based on 12 identified markers.
conclusionOur findings demonstrate a distinct immune profile linked to ICU delirium and illustrate how ML can enhance biomarker discovery. Further prospective validation may refine these markers and guide precision-targeted interventions for mitigating delirium in critically ill populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.